Codis secures growth capital from 1315 Capital to expand its commercial manufacturing capacity in Haverhill, with support from BroadOak Capital Partners and RCT.
BroadOak Capital PartnersResearch Corporation Technologies1315 Capital
Description
Codis, a CDMO focused on commercial spray drying, has announced a growth investment from 1315 Capital, joined by existing shareholders BroadOak Capital Partners and RCT. The funding will accelerate the expansion of Codis's manufacturing capabilities, particularly in Haverhill, UK. This investment is critical for supporting the increasing demand in the pharmaceutical industry for spray-drying expertise. Codis operates one of the largest commercial spray-drying platforms in the world.
Who to call at Codis, and when
A new round usually means Codis is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Codis raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Codis, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Codis
Location
Chesterfield, Missouri, United States
About
Codis is a global CDMO specializing in commercial spray drying, amorphous solid dispersions, particle engineering, and finished dose manufacturing for the pharmaceutical, consumer health, nutraceutical, and OTC sectors. The company combines decades of regulatory expertise and manufacturing strength under one brand. With extensive manufacturing space and multiple GMP facilities, Codis is positioned to help pharmaceutical innovators accelerate therapies from development to market.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Codis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ChesterfieldManufacturingBiotechnologyPharmaceutical